ChinaNationalAccordMedicinesCorporationLtd.
TheThirdQuarterlyReportfor2019
October2019
SectionI.ImportantNoticeBoardofDirectors,SupervisoryCommittee,alldirectors,supervisorsandseniorexecutivesofChinaNationalAccordMedicinesCorporationLtd.(hereinafterreferredtoastheCompany)herebyconfirmthattherearenoanyfictitiousstatements,misleadingstatements,orimportantomissionscarriedinthisreport,andshalltakeallresponsibilities,individualand/orjoint,forthereality,accuracyandcompletionofthewholecontents.AlldirectorsarepresentthemeetingoftheBoardfordeliberatingtheThirdQuarterReportoftheCompanyinperson.LinZhaoxiong,personinchargeoftheCompany,headoftheaccountingworksWeiPingxiaoandWangYing,accountingbodyprincipals(accountantincharge)herebyconfirmthattheFinancialReportoftheThirdQuarterlyReportisauthentic,accurateandcomplete.
SectionII.BasicinformationofCompanyI.MainaccountingdataandfinancialindexesWhetherithasretroactiveadjustmentorre-statementonpreviousaccountingdataornot
□Yes√No
| Currentperiod-end | Period-endoflastyear | Increase/decrease | ||||
| Totalassets(RMB) | 34,816,993,187.67 | 28,930,300,519.97 | 20.35% | |||
| Netassetsattributabletoshareholdersoflistedcompany(RMB) | 12,451,750,624.00 | 11,618,432,603.28 | 7.17% | |||
| Currentperiod | Increase/decreaseincomparisonwithsameperiodoflastyear | Year-begintoendofthePeriod | Increase/decreaseincomparisonwithyear-begintoperiod-endoflastyear | |||
| Operatingrevenue(RMB) | 13,647,793,431.64 | 24.21% | 38,875,940,809.07 | 22.38% | ||
| Netprofitattributabletoshareholdersofthelistedcompany(RMB) | 311,310,706.52 | 9.14% | 962,144,066.92 | 3.79% | ||
| Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB) | 303,365,280.52 | 7.45% | 943,065,728.47 | 4.14% | ||
| Netcashflowarisingfromoperatingactivities(RMB) | -- | -- | 1,072,962,161.22 | 90.24% | ||
| Basicearningspershare(RMB/Share) | 0.735 | 10.36% | 2.247 | 3.79% | ||
| Dilutedearningspershare(RMB/Share) | 0.735 | 10.36% | 2.247 | 3.79% | ||
| WeightedaverageROE | 2.53% | 0.09percentagepointsdecline | 7.94% | 1.27percentagepointsdecline | ||
Note:theweightedaverageROEhas0.09percentagepointsdownfromsameperiodlastyear,and1.27percentagepointsdownatyear-begintoperiod-endoversameperiodlastyear,mainlybecauseastrategyinvestorwasintroducedbyGuodaDrugstoreinsecondhalfoflastyear.Itemsandamountofextraordinaryprofit(gains)/losses
√Applicable□Notapplicable
InRMB
| Item | Amountfromyear-begintoendofthePeriod | Note |
| Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets) | 487,779.48 | |
| Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness) | 29,325,892.83 | Receivedvarytaxessubsidiesandfinancialrewardsintheperiod |
| Reversalofimpairmentreserveforaccountreceivablewithseparateimpairmenttesting | 1,216,744.26 | Netgain/lossofimpairmentprovisionswitch-backforreceivables |
| Gains/lossesonentrustedloans | 2,563,975.31 | ThegainsobtainedfromofferingentrustloanstoChinaNationalZhijun(Suzhou) |
| Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems | 2,455,770.91 | |
| Othergains/lossessatisfyadefinitionofextraordinarygains/losses | 22,424.73 | |
| Less:impactonincometax | 8,393,659.91 | |
| Impactonminorityshareholders’equity(post-tax) | 8,600,589.16 | |
| Total | 19,078,338.45 | -- |
Concerningtheextraordinaryprofit(gain)/lossdefinedbyQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√NotapplicableInreportingperiod,theCompanyhasnoparticularaboutitemsdefinedasrecurringprofit(gain)/lossaccordingtothelistsofextraordinaryprofit(gain)/lossinQ&AAnnouncementNo.1onInformationDisclosureforCompaniesOfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss.
II.Statementofthetotalshareholdersandshares-heldoftoptenshareholdersatendofthePeriod
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders
InShare
| Totalcommonshareholdersattheendofreportperiod | 21,620 | Totalpreferenceshareholderswithvotingrightsrecoveredatendofreportingperiod(ifapplicable) | 0 |
| Toptenshareholders | ||||||
| Shareholders | Natureofshareholder | Proportionofsharesheld | Amountofsharesheld | Amountofrestrictedsharesheld | Numberofsharepledged/frozen | |
| Stateofshare | Amount | |||||
| SinopharmGroupCo.,Ltd. | State-ownedcorporate | 56.06% | 239,999,991 | 55,057,700 | ||
| HongKongSecuritiesClearingCompanyLtd | Overseascorporate | 4.48% | 19,163,870 | |||
| HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | Overseascorporate | 2.68% | 11,469,644 | |||
| ChinaNationalPharmaceuticalForeignTradeCorp. | State-ownedcorporate | 1.24% | 5,323,043 | 5,323,043 | ||
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | Overseascorporate | 1.13% | 4,825,907 | |||
| #BeijingHaoqingFortuneInvestmentManagementCo.,Ltd.–HaoqingValueStableNo.8InvestmentFund | Domesticnonstate-ownedcorporate | 0.96% | 4,118,716 | |||
| Basicendowmentinsurancefund-portfolio1003 | Domesticnonstate-ownedcorporate | 0.95% | 4,080,913 | |||
| CentralHuijinInvestmentLtd. | State-ownedcorporate | 0.89% | 3,804,400 | |||
| BankofChina-HarvestHealthCareStockSecurities | Domesticnonstate-ownedcorporate | 0.76% | 3,258,525 | |||
| InvestmentFunds | ||||||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | Overseascorporate | 0.76% | 3,246,061 | |||
| Particularabouttoptenshareholderswithun-restrictsharesheld | ||||||
| Shareholders | Amountofun-restrictsharesheld | Typeofshares | ||||
| Type | Amount | |||||
| SinopharmGroupCo.,Ltd. | 184,942,291 | RMBordinaryshares | 184,942,291 | |||
| HongKongSecuritiesClearingCompanyLtd | 19,163,870 | RMBordinaryshares | 19,163,870 | |||
| HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD | 11,469,644 | Domesticallylistedforeignshares | 11,469,644 | |||
| ChinaNationalPharmaceuticalForeignTradeCorp. | 5,323,043 | RMBordinaryshares | 5,323,043 | |||
| FidelityInvestmentManagement(HongKong)Limited-Client’sfund | 4,825,907 | RMBordinaryshares | 4,825,907 | |||
| #BeijingHaoqingFortuneInvestmentManagementCo.,Ltd.–HaoqingValueStableNo.8InvestmentFund | 4,118,716 | RMBordinaryshares | 4,118,716 | |||
| Basicendowmentinsurancefund-portfolio1003 | 4,080,913 | RMBordinaryshares | 4,080,913 | |||
| CentralHuijinInvestmentLtd. | 3,804,400 | RMBordinaryshares | 3,804,400 | |||
| BankofChina-HarvestHealthCareStockSecuritiesInvestmentFunds | 3,258,525 | RMBordinaryshares | 3,258,525 | |||
| BBHBOSS/AFIDELITYFD-CHINAFOCUSFD | 3,246,061 | Domesticallylistedforeignshares | 3,246,061 | |||
| Explanationonassociatedrelationshipamongtheaforesaidshareholders | ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies. | |||||
| Explanationontoptencommonshareholdersinvolvingmarginbusiness(ifapplicable) | BeijingHaoQingWealthInvestmentManagementCo.,Ltd.–HaoQingValueStableNo.8InvestmentFundholds4,048,216sharesoftheCompanythroughmargintradingandrefinancingsecuredsecurityaccount | |||||
Whethertoptencommonshareholdersortoptencommonshareholderswithun-restrictsharesheldhaveabuy-backagreement
dealinginreportingperiod
□Yes√NoTheshareholdersoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.Totalofshareholderswithpreferredstockheldandthetoptenshareholdings
□Applicable√Notapplicable
SectionIII.ImportanteventsI.Particularaboutmajorchangesfromitemsofmainaccountingstatementsandfinancialindexesaswellasreasons
√Applicable□Notapplicable
1.Notereceivable:decreased772millionYuanoverthatofperiod-beginwithgrowthrateof-56.88%,mainlybecauseaccordingtothepresentationrequirementsofstatement,atendoftheperiod,thebankacceptancebillinnotereceivablewaslistedundertheitemof“Receivablefinancing”;
2.Accountsreceivable:increased3844millionYuanoverthatofperiod-beginwithgrowthrateof41.17%,mainlybecausevolumeofbusinessincreasedintheperiod,accountreceivablegoesupandpaymentcollectionperiodincreasedatthesametime;
3.Receivablefinancing:increased400millionYuanoverthatofperiod-begin,mainlybecauseaccordingtothepresentationrequirementsofstatement,atendoftheperiod,thebankacceptancebillinnotereceivablewaslistedundertheitemof“Receivablefinancing”;
4.Interestreceivable:increased6.1777millionYuanoverthatofperiod-beginwithgrowthrateof75.12%,mainlybecausethedepositinterestincreased;
5.Right-of-useassets:increased1860millionYuanoverthatofperiod-begin,mainlyduetotheimplementationofnewleasingstandardsintheperiod;
6.Totalnon-currentassets:increased2114millionYuanoverthatofperiod-beginwithgrowthrateof47.66%,mainlybecausetheright-of-useassetsincreasedfornewleasingstandardsimplementedintheperiod;
7.Accountspayable:increased2678millionYuanoverthatofperiod-beginwithgrowthrateof41.41%,mainlybecausevolumeofbusinessincreasedintheperiod,purchasevolumeandaccountpayableincreaseaccordingly;
8.Dividendspayable:increased4.7064millionYuanoverthatofperiod-beginwithgrowthrateof73.66%,mainlybecausetheaccrualofbonusofminorityshareholderspayableincreased;
9.Non-currentliabilitiesduewithinoneyear:increased533millionYuanoverthatofperiod-beginwithgrowthrateof9,093.11%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,theendingbookvalueofleasingliabilitiesdueforrepaymentwithinoneyearfromthebalancesheetdate,waslistedundertheitemof“Non-currentliabilitiesduewithinoneyear”;
10.Othercurrentliabilities:increased330,700Yuanoverthatofperiod-beginwithgrowthrateof113.07%,mainlybecausetheoutputtaxamountreadyfortransferincreasedoverthatofperiod-begin;
11.Long-termborrowings:decreased31.60millionYuanoverthatofperiod-beginwithgrowthrateof-100.00%,mainlybecausethelong-termloanwasre-classifiedtonon-currentliabilityduewithinoneyear;
12.Leaseliabilities:increased1165millionYuanoverthatofperiod-begin,mainlyduetotheimplementationofnewleasingstandardsintheperiod;
13.Long-termpayables:decreased3.764millionYuanoverthatofperiod-beginwithgrowthrateof-82.47%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,thefinanceleasebeforethefirstexecutiondatewasadjustedtoleaseliabilities;
14.Totalnon-currentliabilities:increased1126millionYuanoverthatofperiod-beginwithgrowthrateof422.45%,mainlybecauseleaseliabilitiesincreasedfortheimplementationofnewleasingstandardsintheperiod;
15.Totalliabilities:increased4875millionYuanoverthatofperiod-beginwithgrowthrateof32.44%,mainlybecausevolumeofbusinessincreasedintheperiod,purchasevolumeandaccountpayableincreaseaccordingly;
16.Operatingrevenue:increased7109millionYuanonay-o-ybasiswithgrowthrateof22.38%,mainlybecausebusinessincomeincreasedforthegoodbusinessperformanceintheperiod;
17.Operatingcosts:increased6552millionYuanonay-o-ybasiswithgrowthrateof23.30%,mainlybecausebusinessincomeincreasedforthegoodbusinessperformanceintheperiod,businesscostincreasedcorrespondingly;
18.Financecosts:increased69.5683millionYuanonay-o-ybasiswithgrowthrateof88.87%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,duringtheleaseterms,interestexpensesshallbecalculatedaccordingtothediscountrateforleaseliabilities,therewasnosuchiteminthesameperiodlastyear;
19.Otherincomes:increased14.7031millionYuanonay-o-ybasiswithgrowthrateof118.53%,mainlybecausefiscalsubsidyreceivedinperiodincreased;
20.Impairmentlossesonfinancialassets:increased15.1252millionYuanonay-o-ybasiswithgrowthrateof3156.28%,mainlybecausetheaccountreceivablehasincreasedoversameperiodlastyearatendoftheperiod,thanthebaddebtprovisionaccrualintheperiodincreasedonay-o-ybasis;
21.Impairmentlosses:increased714,900Yuanonay-o-ybasiswithgrowthrateof613.43%,mainlybecausereversaloftheinventoryfallingpricereservesdeclinedfromayearearlier;
22.Gainondisposalofassets:decreased3.7735millionYuanonay-o-ybasiswithgrowthrateof-86.59%,mainlybecauseatsameperiodlastyear,therewasapropertyfundscollectedbythegovernmentwasreceivedbytheCompanywhilenosuchitemintheperiod;
23.Minorityshareholders’gainsandlosses:increased81.7569millionYuanonay-o-ybasiswithgrowthrateof97.93%,mainlybecauseatsecondhalfof2018,subsidiaryGuodaDrugstoreintroducedastrategyinvestor,thegains/lossesofminorityshareholdersincreasedonay-o-ybasisintheperiod;
24.Totalcomprehensiveincomeattributabletominorityshareholders:increased81.7569millionYuanonay-o-ybasiswithgrowthrateof97.93%,mainlybecauseatsecondhalfof2018,subsidiaryGuodaDrugstoreintroducedastrategyinvestor,thetotalcomprehensiveincomeattributabletominorityshareholdersincreasedcorrespondingly;
25.Taxrefunds:increased1.7933millionYuanonay-o-ybasiswithgrowthrateof104.58%,mainlybecausethetaxrefundincreasedcomparedwithsameperiodoflastyear;
26.Cashpaymentsrelatedtootheroperatingactivities:decreased484millionYuanonay-o-ybasiswithgrowthrateof-38.77%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwithotherfinancingactivityconcerned,whilenosuchitematsameperiodlatyear;
27.Netcashflowsfromoperatingactivities:increased509millionYuanonay-o-ybasiswithgrowthrateof90.24%,mainlyduetothegoodoperationperformance,cashreceivedforgoodssalesandprovidingservicesincreasedcorrespondingly;andduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwithotherfinancingactivityconcerned,whilenosuchitematsameperiodlatyear;
28.Cashreceivedfromreturnsoninvestments:decreased52.7204millionYuanonay-o-ybasiswithgrowthrateof-40.26%,mainlybecausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;
29.Cashreceivedwithotherinvestingactivities:decreased96.7471millionYuanonay-o-ybasiswithgrowthrateof-95.54%,mainlybecauseatsameperiodlastyear,receivedaconsiderationforreorganizationofShyndecPharmaceutical,whilenosuchitemintheperiod;
30.Subtotalofcashin-flowfrominvestingactivities:decreased150millionYuanonay-o-ybasiswithgrowthrateof-63.14%,mainlybecausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;andatsameperiodlastyear,receivedaconsiderationforreorganizationofShyndecPharmaceutical,whilenosuchitemintheperiod;
31.Netcashpaidfromdisposalofsubsidiariesandotherbusinessunits:increased5.328millionYuanonay-o-ybasis,mainlyduetotheinvestmentamountfornewcompanyacquisitionintheperiod,whilenosuchitematsameperiodlastyear;
32.Cashpaymentsrelatedtootherinvestingactivities:decreased78.3182millionYuanonay-o-ybasiswithgrowthrateof-97.99%,mainlybecauseatsameperiodlastyear,theentrustedloansofSinopharmZhijun(Suzhou)waspaidwhilenosuchitemintheperiod;
33.Netcashflowsfrominvestingactivities:decreased84.2184millionYuanonay-o-ybasiswithgrowthrateof-102.33%,mainlybecausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;andatsameperiodlastyear,receivedaconsiderationforreorganizationofShyndecPharmaceutical,whilenosuchitemintheperiod;
34.Cashproceedsfrominvestmentsbyothers:decreased2744millionYuanonay-o-ybasiswithgrowthrateof-98.40%,mainlybecauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whilenosuchitemintheperiod;
35.Cashreceivedfromborrowings:decreased32.9702millionYuanonay-o-ybasiswithgrowthrateof-66.38%,mainlybecausethebankcurrentloansintheperioddeclinedonay-o-ybasis;
36.Cashreceiptsrelatedtootherfinancingactivities:decreased107millionYuanonay-o-ybasiswithgrowthrateof-98.19%,mainlybecauseatsameperiodlastyear,receivedamoneyordersecuritywhilenosuchitemintheperiod;
37.Sub-totalofcashinflowsfromfinancingactivities:decreased2884millionYuanonay-o-ybasiswithgrowthrateof-97.86%,mainlybecauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whilenosuchitemintheperiod;
38.Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses:increased174millionYuanonay-o-ybasiswithgrowthrateof62.86%,mainlybecausetheinterestofsupplychainfinancingincreasedonay-o-ybasisintheperiod;
39.Cashpaymentsrelatedtootherfinancingactivities:increased544millionYuanonay-o-ybasiswithgrowthrateof896.87%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwithotherfinancingactivityconcerned,whilenosuchitematsameperiodlatyear;
40.Sub-totalofcashoutflowsfromfinancingactivities:increased712millionYuanonay-o-ybasiswithgrowthrateof170.65%,mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwithotherfinancingactivityconcernedandtheinterestofsupplychainfinancingincreasedonay-o-ybasisintheperiod;
41.Netcashflowsfromfinancingactivities:decreased3596millionYuanonay-o-ybasiswithgrowthrateof-142.10%,mainlybecauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whilenosuchitemintheperiod;
42.Eefectofforeignexchangeratechangesoncashandcashequivalents:increased138,500Yuanonay-o-ybasiswithgrowthrateof44.04%,mainlyduetotheimpactofexchangeratechanges;
43.Netincreaseincashandcashequivalents:decreased3171millionYuanonay-o-ybasiswithgrowthrateof-105.28%,mainlybecauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whilenosuchitemintheperiod;
44.Cashandcashequivalentsatbeginningoftheyear:increased3959millionYuanonay-o-ybasiswithgrowthrateof107.76%,mainlybecauseatsecondhalfoflastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whilenosuchitematperiod-beginoflastyear.II.Progressandinfluenceofthemaineventsaswellassolutionanalysisspecification
□Applicable√NotapplicableProgressofsharesbuy-back
□Applicable√NotapplicableImplementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√Notapplicable
III.Commitmentsthatthecompany,shareholders,actualcontroller,offeror,directors,supervisors,seniormanagementorotherrelatedpartieshavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod
□Applicable√NotapplicableTherearenocommitmentsthatthecompany,shareholders,actualcontroller,offeror,directors,supervisors,seniormanagementorotherrelatedpartieshavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod.IV.Particularaboutsecurityinvestment
□Applicable√NotapplicableTheCompanyhadnosecurityinvestmentinPeriod.V.Trustfinancing
□Applicable√NotapplicableTheCompanyhadnotrustfinancinginPeriod.VI.Particularsaboutderivativesinvestment
□Applicable√NotapplicableTheCompanyhadnoderivativesinvestmentinPeriod.VII.Registrationformofreceivingresearch,communicationandinterviewinthereportperiod
□Applicable√NotapplicableTheCompanyhasnoresearch,communicationandinterviewacceptedinthePeriod.VIII.Guaranteeoutsideagainsttheregulation
□Applicable√NotapplicableTheCompanyhadnoguaranteeoutsideagainsttheregulationinthereportingperiod.
IX.Non-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty
□Applicable√NotapplicableTheCompanyhadnonon-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty.
SectionIV.FinancialStatementI.Financialstatement
1.Consolidatebalancesheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
2019-09-30
InRMB
| Item | 2019-9-30 | 2018-12-31 |
| Currentassets: | ||
| Monetaryfunds | 7,810,810,868.51 | 8,089,781,304.56 |
| Settlementprovisions | ||
| Capitallent | ||
| Tradablefinancialassets | ||
| Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | ||
| Derivativefinancialassets | ||
| Notereceivable | 585,211,751.81 | 1,357,311,929.63 |
| Accountreceivable | 13,181,036,029.36 | 9,336,861,647.92 |
| Receivablefinancing | 400,387,183.26 | |
| Advancestosuppliers | 424,448,767.10 | 583,484,515.95 |
| Insurancereceivable | ||
| Reinsurancereceivables | ||
| Contractreserveofreinsurancereceivable | ||
| Otherreceivables | 522,497,740.14 | 643,493,359.32 |
| Including:Interestreceivable | 14,401,063.47 | 8,223,327.64 |
| Dividendreceivable | ||
| Buyingbackthesaleoffinancialassets | ||
| Inventories | 5,274,930,261.55 | 4,389,335,942.19 |
| Contractualassets | ||
| Assetsheldforsale |
| Non-currentassetduewithinoneyear | ||
| Othercurrentassets | 69,262,261.99 | 95,347,629.18 |
| Totalcurrentassets | 28,268,584,863.72 | 24,495,616,328.75 |
| Non-currentassets: | ||
| Loansandpaymentsonbehalf | ||
| Debtinvestment | ||
| Financeassetavailableforsales | ||
| Otherdebtinvestment | ||
| Held-to-maturityinvestment | ||
| Long-termaccountreceivable | ||
| Long-termequityinvestment | 2,107,690,039.44 | 1,880,393,786.10 |
| Otherequityinstrumentsinvestment | 13,685,760.00 | 13,685,760.00 |
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
| Investmentproperties | 139,672,194.89 | 144,894,495.97 |
| Fixedassets | 583,995,191.53 | 607,933,827.67 |
| Constructioninprogress | 35,681,041.39 | 36,412,614.61 |
| Productivebiologicalasset | ||
| Oilandgasasset | ||
| Right-of-useassets | 1,860,064,348.67 | |
| Intangibleassets | 314,251,903.10 | 319,207,126.15 |
| ExpenseonResearchandDevelopment | ||
| Goodwill | 871,041,800.60 | 833,547,800.60 |
| Long-termprepaidexpenses | 330,156,094.79 | 311,328,706.46 |
| Deferredtaxassets | 78,340,768.87 | 74,914,209.95 |
| Othernon-currentasset | 73,829,180.67 | 72,365,863.71 |
| Totalnon-currentasset | 6,548,408,323.95 | 4,434,684,191.22 |
| Totalassets | 34,816,993,187.67 | 28,930,300,519.97 |
| Currentliabilities: | ||
| Short-termborrowings | 2,417,214,478.23 | 2,597,652,702.43 |
| Loanfromcentralbank | ||
| Capitalborrowed | ||
| Transactionalfinancialliability |
| Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | ||
| Derivativefinancialliability | ||
| Notepayable | 4,087,524,569.31 | 3,416,755,681.80 |
| Accountpayable | 9,146,870,315.29 | 6,468,535,961.17 |
| Accountsreceivedinadvance | ||
| Contractualliability | 226,493,600.53 | 255,590,612.37 |
| Sellingfinancialassetofrepurchase | ||
| Absorbingdepositandinterbankdeposit | ||
| Securitytradingofagency | ||
| Securitysalesofagency | ||
| Employeebenefitspayable | 208,422,163.84 | 231,866,407.40 |
| Taxespayable | 240,761,116.26 | 241,980,412.72 |
| Otheraccountpayable | 1,639,777,109.48 | 1,539,436,971.93 |
| Incl:Interestpayable | 23,295,353.88 | 21,906,660.63 |
| Dividendpayable | 11,095,744.80 | 6,389,320.96 |
| Commissionchargeandcommissionpayable | ||
| Reinsurancepayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 538,837,869.81 | 5,861,324.37 |
| Othercurrentliabilities | 623,159.83 | 292,465.75 |
| Totalcurrentliabilities | 18,506,524,382.58 | 14,757,972,539.94 |
| Non-currentliabilities: | ||
| Insurancecontractreserve | ||
| Long-termborrowings | 31,600,000.00 | |
| Bondspayable | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliability | 1,165,308,548.15 | |
| Long-termpayable | 800,000.00 | 4,563,978.52 |
| Long-termemployeebenefitspayable | 1,915,000.00 | 2,050,000.00 |
| Accrualliability | ||
| Deferredincome | 90,111,450.25 | 91,491,170.40 |
| Deferredtaxliabilities | 66,067,559.30 | 67,605,161.88 |
| Othernon-currentliabilities | 68,388,290.57 | 69,241,176.18 |
| Totalnon-currentliabilities | 1,392,590,848.27 | 266,551,486.98 |
| Totalliabilities | 19,899,115,230.85 | 15,024,524,026.92 |
| Owner’sequity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:Preferredstock | ||
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,363,409,728.51 | 4,320,984,981.51 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | ||
| Reasonablereserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Provisionofgeneralrisk | ||
| Retainedearnings | 7,446,150,420.99 | 6,655,257,147.27 |
| Shareholders’equityattributabletoshareholdersoftheparent | 12,451,750,624.00 | 11,618,432,603.28 |
| Non-controllinginterests | 2,466,127,332.82 | 2,287,343,889.77 |
| Totalshareholders’equity | 14,917,877,956.82 | 13,905,776,493.05 |
| Totalliabilitiesandshareholders’equity | 34,816,993,187.67 | 28,930,300,519.97 |
Legalrepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitution:WangYing
2.BalanceSheetofParentCompany
InRMB
| Item | 2019-9-30 | 2018-12-31 |
| Currentassets: | ||
| Cashandbankbalances | 2,544,212,671.60 | 1,817,654,598.01 |
| Tradablefinancialassets |
| Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | ||
| Derivativefinancialassets | ||
| Notereceivable | 33,503,980.32 | 63,870,980.39 |
| Accountreceivable | 759,614,729.17 | 631,236,593.94 |
| Receivablefinancing | 16,673,997.31 | |
| Advancestosuppliers | 3,026,025.81 | 4,760,182.00 |
| Otherreceivable | 1,866,735,563.06 | 1,541,980,883.50 |
| Including:Interestreceivable | 16,497,156.40 | 7,550,877.07 |
| Dividendreceivable | ||
| Inventories | 211,858,298.59 | 158,166,185.65 |
| Contractualassets | ||
| Assetsheldforsale | ||
| Non-currentassetsmaturingwithinoneyear | ||
| Othercurrentassets | 39,482.38 | 39,482.38 |
| Totalcurrentassets | 5,435,664,748.24 | 4,217,708,905.87 |
| Non-currentassets: | ||
| Debtinvestment | ||
| Available-for-salefinancialassets | ||
| Otherdebtinvestment | ||
| Held-to-maturityinvestments | ||
| Long-termreceivables | ||
| Long-termequityinvestments | 7,693,092,094.23 | 7,432,906,692.24 |
| Investmentinotherequityinstrument | ||
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 |
| Investmentproperties | 1,560,072.33 | 1,955,854.46 |
| Fixedassets | 15,474,034.96 | 21,362,422.03 |
| Constructioninprogress | ||
| Productivebiologicalassets | ||
| Oilandnaturalgasassets | ||
| Right-of-useassets | 6,500,265.79 | |
| Intangibleassets | 2,783,945.44 | 2,452,222.51 |
| Researchanddevelopmentcosts | ||
| Goodwill | ||
| Long-termdeferredexpenses | 6,527,719.68 | 7,481,809.53 |
| Deferredincometaxassets | ||
| Othernon-currentassets | 7,000,000.00 | 7,000,000.00 |
| Totalnon-currentassets | 7,872,938,132.43 | 7,613,159,000.77 |
| Totalassets | 13,308,602,880.67 | 11,830,867,906.64 |
| Currentliabilities: | ||
| Short-termborrowings | 280,000,000.00 | 539,000,000.00 |
| Transactionalfinancialliability | ||
| Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | ||
| Derivativefinancialliability | ||
| Notespayable | 390,519,916.75 | 252,317,800.78 |
| Accountpayable | 630,198,511.72 | 442,049,241.22 |
| Accountsreceivedinadvance | ||
| Contractualliability | 1,694,562.86 | 4,182,083.40 |
| Employeebenefitspayable | 37,876,995.85 | 36,233,563.12 |
| Taxespayable | 9,336,735.58 | 13,426,601.90 |
| Otherpayable | 1,894,492,989.75 | 1,481,817,856.56 |
| Incl:Interestpayable | 8,063,589.67 | 1,354,592.35 |
| Dividendspayable | ||
| Liabilityheldforsale | ||
| Non-currentliabilitiesduewithinoneyear | 32,573,100.20 | |
| Othercurrentliabilities | 292,740.68 | 226,427.99 |
| Totalcurrentliabilities | 3,276,985,553.39 | 2,769,253,574.97 |
| Non-currentliabilities: | ||
| Long-termborrowings | 31,600,000.00 | |
| Bondspayable | ||
| Including:preferredstock | ||
| Perpetualcapitalsecurities | ||
| Leaseliabilities | 5,715,312.04 |
| Long-termpayables | 800,000.00 | 800,000.00 |
| Long-termemployeebenefitspayable | 102,000.00 | 118,000.00 |
| Accruedliabilities | ||
| Deferredincome | 1,388,958.78 | 1,687,899.50 |
| Deferredtaxliabilities | 1,644,875.80 | 2,298,426.39 |
| Othernon-currentliabilities | ||
| Totalnon-currentliabilities | 9,651,146.62 | 36,504,325.89 |
| Totalliabilities | 3,286,636,700.01 | 2,805,757,900.86 |
| Owners’equity: | ||
| Sharecapital | 428,126,983.00 | 428,126,983.00 |
| Otherequityinstrument | ||
| Including:preferredstock | ||
| Perpetualcapitalsecurities | ||
| Capitalsurplus | 4,468,787,524.26 | 4,426,362,777.26 |
| Less:Inventoryshares | ||
| Othercomprehensiveincome | ||
| Specialreserve | ||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 |
| Retainedearnings | 4,910,988,181.90 | 3,956,556,754.02 |
| Totalshareholders’equity | 10,021,966,180.66 | 9,025,110,005.78 |
| Totalliabilitiesandshareholders’equity | 13,308,602,880.67 | 11,830,867,906.64 |
3.ConsolidatedProfitStatement(theperiod)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Totaloperatingrevenue | 13,647,793,431.64 | 10,987,540,368.77 |
| Including:Operatingrevenue | 13,647,793,431.64 | 10,987,540,368.77 |
| Interestrevenue | ||
| Insurancegained | ||
| Commissionchargeandcommissionrevenue | ||
| II.Totaloperatingcosts | 13,305,315,433.53 | 10,672,195,431.17 |
| Including:Operatingcosts | 12,253,508,326.76 | 9,749,853,630.20 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue | ||
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 36,513,174.49 | 30,175,966.21 |
| Sellingexpense | 763,231,928.31 | 682,736,449.56 |
| Administrativeexpense | 208,311,402.38 | 188,693,332.32 |
| R&Dexpense | ||
| Financecosts | 43,750,601.59 | 20,736,052.88 |
| Incl:Interestcost | 86,528,994.84 | 45,676,535.07 |
| Interestincome | 42,778,570.08 | 26,253,068.71 |
| Add:otherincome | 12,116,753.12 | 1,815,373.95 |
| Investmentincome(Lossislistedwith“-”) | 86,069,936.49 | 78,983,284.46 |
| Incl:Investmentincomefromassociates | 86,019,936.49 | 78,933,284.46 |
| Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”) | ||
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Impairmentlossesonfinancialassets(Lossislistedwith“-”) | -3,211,918.65 | -547,491.37 |
| Impairmentlosses(Lossislistedwith“-”) | -705,879.81 | 392,308.58 |
| Gainondisposalofassets(Lossislistedwith“-”) | 613,909.71 | 76,479.50 |
| III.Operatingprofit(Lossislistedwith | 437,360,798.97 | 396,064,892.72 |
| “-”) | ||
| Add:Non-operatingincome | 3,202,332.16 | 1,553,611.12 |
| Less:Non-operatingexpense | 638,789.06 | 374,027.37 |
| IV.Totalprofit(Lossislistedwith“-”) | 439,924,342.07 | 397,244,476.47 |
| Less:Incometaxes | 80,632,027.90 | 76,038,019.79 |
| V.Netprofit(Netlossislistedwith“-”) | 359,292,314.17 | 321,206,456.68 |
| (i)Classifybybusinesscontinuity | ||
| 1.NetProfitfromcontinuingoperations(netlosslistedwith‘-”) | 359,292,314.17 | 321,206,456.68 |
| 2.terminationofnetprofit(netlosslistedwith‘-”) | ||
| (ii)Attributableto | ||
| 1.Ownersoftheparent | 311,310,706.52 | 285,244,535.54 |
| 2.Non-controllinginterests | 47,981,607.65 | 35,961,921.14 |
| VI.Netafter-taxofothercomprehensiveincome | ||
| Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany | ||
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss |
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets | ||
| 4.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset | ||
| 6.Creditimpairmentprovisionforotherdebtinvestment | ||
| 7.Cashflowhedgingreserve | ||
| 8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 9.Other | ||
| Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
| VII.Totalcomprehensiveincome | 359,292,314.17 | 321,206,456.68 |
| Totalcomprehensiveincomefortheyearattributabletoshareholdersoftheparent | 311,310,706.52 | 285,244,535.54 |
| Totalcomprehensiveincomefortheyearattributabletonon-controllinginterests | 47,981,607.65 | 35,961,921.14 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 0.735 | 0.666 |
| (ii)Dilutedearningspershare | 0.735 | 0.666 |
AsforthebusinessmergerunderthesamecontrolinthePeriod,0Yuannetprofitrealizedbeforemergerbythecombinedparty,thenetprofitforcombinedpartyinlastperiodwas0Yuan.Legalrepresentative:LinZhaoxiongPersoninchargeofaccountingworks:WeiPingxiaoPersoninchargeofaccountinginstitution:WangYing
4.ProfitStatementofParentCompany(theperiod)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Operatingrevenue | 1,112,624,846.96 | 899,859,002.45 |
| Less:Operatingcosts | 1,064,701,021.03 | 856,296,603.88 |
| Taxandsurcharge | 1,964,184.59 | 1,445,734.44 |
| Sellingexpenses | 17,984,619.36 | 16,953,141.79 |
| Administrativeexpenses | 24,299,300.83 | 16,785,749.55 |
| R&Dexpenses | ||
| Financialcosts | -11,487,202.76 | -10,270,272.65 |
| Incl:Interestexpense | 15,442,321.41 | 10,951,050.33 |
| Incl:Interestincome | 27,695,670.05 | 21,345,942.02 |
| Add:otherincome | 219,828.06 | 121,990.82 |
| Investmentincome(Lossislistedwith“-”) | 473,512,554.91 | 84,991,405.06 |
| Incl:Investmentincomefromassociates | 91,259,842.03 | 84,991,405.06 |
| Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Impairmentlossesonfinancialassets(Lossislistedwith“-”) | -161,522.25 | |
| Impairmentloss(Lossislistedwith“-”) | -234,019.78 | 152,059.06 |
| Gainondisposalofassets(Lossislistedwith“-”) | 181,433.34 | 11,116.50 |
| II.Operatingprofits(Lossislistedwith“-”) | 488,681,198.19 | 103,924,616.88 |
| Add:Non-operatingincome | 373.35 | 3.98 |
| Less:Non-operatingexpense | ||
| III.TotalProfit(Lossislistedwith“-”) | 488,681,571.54 | 103,924,620.86 |
| Less:Incometaxes | 3,675,740.93 | 4,806,491.84 |
| IV.Netprofit(Netlossislistedwith“-”) | 485,005,830.61 | 99,118,129.02 |
| (i)NetProfitfromcontinuingoperations(netlosslistedwith‘-”) | 485,005,830.61 | 99,118,129.02 |
| (ii)terminationofnetprofit(netlosslistedwith‘-”) | ||
| V.Netafter-taxofothercomprehensiveincome | ||
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeofenterprise'screditrisk | ||
| 5.Other | ||
| (II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets | ||
| 4.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset | ||
| 6.Creditimpairmentprovisionforotherdebtinvestment |
| 7.Cashflowhedgingreserve | ||
| 8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 9.Other | ||
| VI.Totalcomprehensiveincome | 485,005,830.61 | 99,118,129.02 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
5.ConsolidatedProfitStatement(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Totaloperatingrevenue | 38,875,940,809.07 | 31,766,707,068.44 |
| Including:Operatingrevenue | 38,875,940,809.07 | 31,766,707,068.44 |
| Interestrevenue | ||
| Insurancegained | ||
| Commissionchargeandcommissionrevenue | ||
| II.Totaloperatingcost | 37,747,619,061.94 | 30,779,410,046.43 |
| Including:Operatingcosts | 34,669,028,279.63 | 28,117,497,354.04 |
| Interestexpense | ||
| Commissionchargeandcommissionexpense | ||
| Cashsurrendervalue | ||
| Netamountofexpenseofcompensation | ||
| Netamountofwithdrawalofinsurancecontractreserve | ||
| Bonusexpenseofguaranteeslip | ||
| Reinsuranceexpense | ||
| Taxandsurcharges | 98,652,400.93 | 86,796,493.46 |
| Sallingexpenses | 2,246,564,429.04 | 1,956,325,205.63 |
| Administrativeexpenses | 585,528,096.51 | 540,513,396.10 |
| R&Dexpense |
| Financecosts | 147,845,855.83 | 78,277,597.20 |
| Incl:Interestcost | 256,058,467.21 | 129,032,902.25 |
| Interestincome | 103,408,606.99 | 49,335,302.27 |
| Add:otherincomes | 27,107,672.14 | 12,404,586.52 |
| Investmentincome(Lossislistedwith“-”) | 255,212,226.48 | 241,677,055.81 |
| Incl:Investmentincomefromassociates | 255,162,226.48 | 241,595,555.81 |
| Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”) | ||
| Exchangeincome(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Incomefromchangeoffairvalue(Lossislistedwith“-”) | ||
| Impairmentlossesonfinancialassets(Lossislistedwith“-”) | -14,646,019.78 | 479,210.87 |
| Impairmentlosses(Lossislistedwith“-”) | -831,434.15 | -116,540.68 |
| Gainondisposalofassets(Lossislistedwith“-”) | 584,184.27 | 4,357,644.11 |
| III.Operatingprofit(Lossislistedwith“-”) | 1,395,748,376.09 | 1,246,098,978.64 |
| Add:Non-operatingincome | 6,869,502.41 | 7,052,562.23 |
| Less:Non-operatingexpense | 2,357,054.62 | 2,171,320.17 |
| IV.Totalprofit(Lossislistedwith“-”) | 1,400,260,823.88 | 1,250,980,220.70 |
| Less:Incometaxes | 272,875,954.40 | 240,524,754.11 |
| V.Netprofit(Netlossislistedwith“-”) | 1,127,384,869.48 | 1,010,455,466.59 |
| (i)Classifybybusinesscontinuity | ||
| 1.NetProfitfromcontinuingoperations(netlosslistedwith‘-”) | 1,127,384,869.48 | 1,010,455,466.59 |
| 2.terminationofnetprofit(netlosslistedwith‘-”) | ||
| (ii)Classifybyownership | ||
| 1.Ownersoftheparent | 962,144,066.92 | 926,971,570.47 |
| 2.Non-controllinginterests | 165,240,802.56 | 83,483,896.12 |
| VI.Netafter-taxofothercomprehensiveincome |
| Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany |
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss |
| 1.Changesofthedefinedbenefitplansthatre-measured |
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss |
| 3.Changeoffairvalueofinvestmentinotherequityinstrument |
| 4.Fairvaluechangeofenterprise'screditrisk |
| 5.Other |
| (ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss |
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss |
| 2.Changeoffairvalueofotherdebtinvestment |
| 3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets |
| 4.Amountoffinancialassetsre-classifytoothercomprehensiveincome |
| 5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset |
| 6.Creditimpairmentprovisionforotherdebtinvestment |
| 7.Cashflowhedgingreserve |
| 8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 9.Other | ||
| Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders | ||
| VII.Totalcomprehensiveincome | 1,127,384,869.48 | 1,010,455,466.59 |
| Totalcomprehensiveincomefortheyearattributabletoshareholdersoftheparent | 962,144,066.92 | 926,971,570.47 |
| Totalcomprehensiveincomefortheyearattributabletonon-controllinginterests | 165,240,802.56 | 83,483,896.12 |
| VIII.Earningspershare: | ||
| (i)Basicearningspershare | 2.247 | 2.165 |
| (ii)Dilutedearningspershare | 2.247 | 2.165 |
AsforthebusinessmergerunderthesamecontrolinthePeriod,0Yuannetprofitrealizedbeforemergerbythecombinedparty,thenetprofitforcombinedpartyinlastperiodwas0Yuan.
6.ProfitStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Operatingrevenue | 3,120,629,410.26 | 2,587,480,358.28 |
| Less:Operatingcosts | 2,985,973,415.79 | 2,471,014,077.79 |
| Taxesandsurcharge | 4,483,432.58 | 3,462,103.37 |
| Sellingexpenses | 49,036,664.17 | 42,847,937.24 |
| Administrativeexpenses | 62,356,107.14 | 50,464,856.30 |
| R&Dexpenses | ||
| Financecosts | -39,885,446.76 | -29,640,152.73 |
| Incl:Interestexpense | 38,713,629.13 | 31,721,163.76 |
| Incl:Interestincome | 80,175,392.47 | 62,271,142.76 |
| Add:otherincome | 552,592.19 | 1,421,335.96 |
| Investmentincome(Lossislistedwith“-”) | 1,081,800,975.38 | 619,832,149.52 |
| Incl:Investmentincomefromassociates | 272,540,375.14 | 258,317,695.20 |
| Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”) | ||
| Netexposurehedgingincome(Lossislistedwith“-”) | ||
| Changingincomeoffairvalue(Lossislistedwith“-”) | ||
| Impairmentlossesonfinancialassets(Lossislistedwith“-”) | -2,527,287.33 | 7,411.02 |
| Impairmentloss(Lossislistedwith“-”) | -336,132.62 | -478,894.27 |
| Gainondisposalofassets(Lossislistedwith“-”) | 155,358.82 | 11,116.50 |
| II.Operatingprofit(Lossislistedwith“-”) | 1,138,310,743.78 | 670,124,655.04 |
| Add:Non-operatingincome | 46,442.75 | 37.06 |
| Less:Non-operatingexpenses | 127,688.63 | |
| III.TotalProfit(Lossislistedwith“-”) | 1,138,357,186.53 | 669,997,003.47 |
| Less:Incometaxes | 12,674,965.45 | 11,099,365.68 |
| IV.Netprofit(Netlossislistedwith“-”) | 1,125,682,221.08 | 658,897,637.79 |
| (i)NetProfitfromcontinuingoperations(netlosslistedwith‘-”) | 1,125,682,221.08 | 658,897,637.79 |
| (ii)terminationofnetprofit(netlosslistedwith‘-”) | ||
| V.Netafter-taxofothercomprehensiveincome | ||
| (I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss | ||
| 1.Changesofthedefinedbenefitplansthatre-measured | ||
| 2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss | ||
| 3.Changeoffairvalueofinvestmentinotherequityinstrument | ||
| 4.Fairvaluechangeof |
| enterprise'screditrisk | ||
| 5.Other | ||
| (II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss | ||
| 1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss | ||
| 2.Changeoffairvalueofotherdebtinvestment | ||
| 3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets | ||
| 4.Amountoffinancialassetsre-classifytoothercomprehensiveincome | ||
| 5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset | ||
| 6.Creditimpairmentprovisionforotherdebtinvestment | ||
| 7.Cashflowhedgingreserve | ||
| 8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements | ||
| 9.Other | ||
| VI.Totalcomprehensiveincome | 1,125,682,221.08 | 658,897,637.79 |
| VII.Earningspershare: | ||
| (i)Basicearningspershare | ||
| (ii)Dilutedearningspershare |
7.ConsolidatedCashFlowStatement(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Cashflowsarisingfromoperatingactivities: |
| Cashreceivedfromsalesofgoodorrenderingofservices | 39,464,106,244.18 | 33,576,126,717.79 |
| Netincreaseofcustomerdepositandinterbankdeposit | ||
| Netincreaseofloanfromcentralbank | ||
| Netincreaseofcapitalborrowedfromotherfinancialinstitution | ||
| Cashreceivedfromoriginalinsurancecontractfee | ||
| Netcashreceivedfromreinsurancebusiness | ||
| Netincreaseofinsuredsavingsandinvestment | ||
| Cashreceivedfrominterest,commissionchargeandcommission | ||
| Netincreaseofcapitalborrowed | ||
| Netincreaseofreturnedbusinesscapital | ||
| Netcashreceivedbyagentsinsaleandpurchaseofsecurities | ||
| Taxrefunds | 3,508,074.72 | 1,714,760.21 |
| Cashreceiptsrelatedtootheroperatingactivities | 497,412,494.23 | 503,409,429.80 |
| Sub-totalofcashinflowsfromoperatingactivities | 39,965,026,813.13 | 34,081,250,907.80 |
| Cashpaidforgoodsandservices | 35,594,093,946.44 | 30,058,268,141.08 |
| Netincreaseofcustomerloansandadvances | ||
| Netincreaseofdepositsincentralbankandinterbank | ||
| Cashpaidfororiginalinsurancecontractcompensation | ||
| Netincreaseofcapitallent | ||
| Cashpaidforinterest,commissionchargeandcommission | ||
| Cashpaidforbonusofguaranteeslip |
| Cashpaidtoandonbehalfofemployees | 1,592,033,194.68 | 1,392,220,211.12 |
| Cashpaidforalltypesoftaxes | 941,789,797.45 | 818,864,295.31 |
| Cashpaymentsrelatedtootheroperatingactivities | 764,147,713.34 | 1,247,906,964.93 |
| Sub-totalofcashoutflowsfromoperatingactivities | 38,892,064,651.91 | 33,517,259,612.44 |
| Netcashflowsfromoperatingactivities | 1,072,962,161.22 | 563,991,295.36 |
| II.Cashflowsarisingfrominvestingactivities: | ||
| Cashreceivedfromrecoveringinvestment | ||
| Cashreceivedfromreturnsoninvestments | 78,242,963.78 | 130,963,345.37 |
| Netcashreceivedfromdisposaloffixed,intangibleassetsandotherlong-termassets | 4,967,658.92 | 5,751,674.16 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Cashreceiptsrelatedtootherinvestingactivities | 4,514,498.90 | 101,261,607.73 |
| Sub-totalofcashinflowsfrominvestingactivities | 87,725,121.60 | 237,976,627.26 |
| Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 162,770,914.81 | 150,353,192.93 |
| Cashpaidforacquisitionofinvestments | 84,539,317.61 | 90,000,000.00 |
| Netincreaseofmortgagedloans | ||
| Netcashpaidfromdisposalofsubsidiariesandotherbusinessunits | 5,328,000.00 | |
| Cashpaymentsrelatedtootherinvestingactivities | 1,603,306.28 | 79,921,476.82 |
| Sub-totalofcashoutflowsfrominvestingactivitiesactivities | 254,241,538.70 | 320,274,669.75 |
| Netcashflowsarisingfrominvestingactivities | -166,516,417.10 | -82,298,042.49 |
| III.Cashflowsarisingfromfinancing |
| activities | ||
| Cashproceedsfrominvestmentsbyothers | 44,548,000.00 | 2,788,851,200.00 |
| Incl:Cashproceedsfromsubsidiaryinvestmentsbynon-controllingshareholders | 44,548,000.00 | 2,788,851,200.00 |
| Cashreceivedfromborrowings | 16,700,000.00 | 49,670,200.30 |
| Cashreceiptsrelatedtootherfinancingactivities | 1,967,629.61 | 108,949,307.54 |
| Subtotalofcashinflowfromfinancingactivities | 63,215,629.61 | 2,947,470,707.84 |
| Cashrepaymentsfordebts | 73,307,142.79 | 79,670,200.30 |
| Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses | 450,504,620.79 | 276,628,059.98 |
| Incl:Profitanddividendspaidtonon-controllingshareholdersofsubsidiaries | 28,493,123.11 | 56,858,945.30 |
| Cashpaymentsrelatedtootherfinancingactivitiess | 604,680,365.03 | 60,658,096.82 |
| Subtotalofcashoutflowfromfinancingactivities | 1,128,492,128.61 | 416,956,357.10 |
| Netcashflowsfromfinancingactivities | -1,065,276,499.00 | 2,530,514,350.74 |
| IV.EffectofforeignexchangeratechangesoncashandcashequivalentsInfluenceoncashandcashequivalentsduetofluctuationinexchangerate | -175,994.42 | -314,517.97 |
| V.Netincreaseincashandcashequivalents | -159,006,749.30 | 3,011,893,085.64 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 7,632,117,020.77 | 3,673,498,691.48 |
| VI.Cashandcashequivalentsatendofyear | 7,473,110,271.47 | 6,685,391,777.12 |
8.CashFlowStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
| Item | CurrentPeriod | LastPeriod |
| I.Cashflowsarisingfromoperatingactivities: |
| Cashreceivedfromsalesofgoodorrenderingofservices | 3,217,890,947.38 | 2,681,236,630.70 |
| Write-backoftaxreceived | ||
| Cashreceiptsrelatedtootheroperatingactivities | 32,674,054.58 | 91,958,196.80 |
| Sub-totalofcashinflowsfromoperatingactivities | 3,250,565,001.96 | 2,773,194,827.50 |
| Cashpaidforgoodsandservices | 3,191,926,190.64 | 2,559,377,589.52 |
| Cashpaidtoandonbehalfofemployees | 73,601,798.69 | 61,913,310.95 |
| Cashpaidforalltypesoftaxes | 43,156,828.71 | 29,801,808.96 |
| Cashpaymentsrelatedtootheroperatingactivities | 24,724,274.57 | 45,140,599.54 |
| Subtotalofcashoutflowfromoperatingactivities | 3,333,409,092.61 | 2,696,233,308.97 |
| Netcashflowsarisingfromoperatingactivities | -82,844,090.65 | 76,961,518.53 |
| II.Cashflowsarisingfrominvestingactivities: | ||
| Cashreceivedfromrecoveringinvestment | ||
| Cashreceivedfromreturnsofinvestments | 619,976,538.54 | 255,904,643.39 |
| Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets | 3,961,383.00 | 35,200.00 |
| Netcashreceivedfromdisposalofsubsidiariesandotherunits | ||
| Cashreceiptsrelatedtootherinvestingactivities | 1,482,390,000.00 | 1,218,035,586.01 |
| Subtotalofcashinflowfrominvestingactivities | 2,106,327,921.54 | 1,473,975,429.40 |
| Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets | 6,777,035.03 | 8,607,026.77 |
| Cashpaidforinvestment | 19,998,000.00 | 90,000,000.00 |
| Netcashreceivedfromsubsidiariesandotherunitsobtained |
| Cashpaymentsrelatedtootherinvestingactivities | 1,812,850,181.28 | 1,267,321,606.82 |
| Subtotalofcashoutflowfrominvestingactivities | 1,839,625,216.31 | 1,365,928,633.59 |
| Netcashflowsfrominvestingactivitiesactivities | 266,702,705.23 | 108,046,795.81 |
| III.Cashflowsarisingfromfinancingactivities: | ||
| Cashreceivedfromabsorbinginvestment | ||
| Cashreceivedfromborrowings | 10,000,000.00 | 10,000,000.00 |
| Cashreceiptsrelatedtootherfinancingactivities | 18,437,509,464.22 | 12,559,913,378.52 |
| Subtotalofcashinflowfromfinancingactivities | 18,447,509,464.22 | 12,569,913,378.52 |
| Cashrepaymentsfordebts | 10,000,000.00 | 10,000,000.00 |
| Cashpaymentsfordistributionofdividends,profitorinterestexpenses | 191,576,803.94 | 153,116,428.79 |
| Cashpaymentsrelatedtootherfinancingactivities | 17,703,057,206.85 | 12,723,602,657.57 |
| Subtotalofcashoutflowfromfinancingactivities | 17,904,634,010.79 | 12,886,719,086.36 |
| Netcashflowsfromfinancingactivities | 542,875,453.43 | -316,805,707.84 |
| IV..Effectofforeignexchangeratechangesoncashandcashequivalents | -175,994.42 | -314,517.97 |
| V.Netincreaseincashandcashequivalents | 726,558,073.59 | -132,111,911.47 |
| Add:Cashandcashequivalentsatbeginningoftheyear | 1,817,654,598.01 | 1,776,696,342.87 |
| VI.Cashandcashequivalentsatendofyear | 2,544,212,671.60 | 1,644,584,431.40 |
II.Financialstatementadjustment
1.Relevantitemsofthefinancialstatementatbeginningoftheyearwhenimplementingthenewfinancialinstrumentstandards,newrevenuestandardsornewleasingstandardssince2019
√Applicable□NotapplicableConsolidatedBalanceSheet
InRMB
| Item | 2018-12-31 | 2019-01-01 | Adjustment |
| Currentassets: | |||
| Monetaryfunds | 8,089,781,304.56 | 8,089,781,304.56 | |
| Settlementprovisions | |||
| Capitallent | |||
| Tradablefinancialassets | |||
| Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | |||
| Derivativefinancialassets | |||
| Notereceivable | 1,357,311,929.63 | 789,536,654.23 | -567,775,275.40 |
| Accountreceivable | 9,336,861,647.92 | 9,336,861,647.92 | |
| Receivablefinancing | 567,775,275.40 | 567,775,275.40 | |
| Advancestosuppliers | 583,484,515.95 | 419,443,944.83 | -164,040,571.12 |
| Insurancereceivable | |||
| Reinsurancereceivables | |||
| Contractreserveofreinsurancereceivable | |||
| Otherreceivables | 643,493,359.32 | 643,493,359.32 | |
| Including:Interestreceivable | 8,223,327.64 | 8,223,327.64 | |
| Dividendreceivable | |||
| Buyingbackthesaleoffinancialassets | |||
| Inventories | 4,389,335,942.19 | 4,389,335,942.19 | |
| Contractualassets | |||
| Assetsheldforsale | |||
| Non-currentassetduewithinoneyear | |||
| Othercurrentassets | 95,347,629.18 | 95,347,629.18 | |
| Totalcurrentassets | 24,495,616,328.75 | 24,331,575,757.63 | -164,040,571.12 |
| Non-currentassets: |
| Loansandpaymentsonbehalf | |||
| Debtinvestment | |||
| Financeassetavailableforsales | |||
| Otherdebtinvestment | |||
| Held-to-maturityinvestment | |||
| Long-termaccountreceivable | |||
| Long-termequityinvestment | 1,880,393,786.10 | 1,880,393,786.10 | |
| Otherequityinstrumentsinvestment | 13,685,760.00 | 13,685,760.00 | |
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 | |
| Investmentproperties | 144,894,495.97 | 144,894,495.97 | |
| Fixedassets | 607,933,827.67 | 594,067,973.91 | -13,865,853.76 |
| Constructioninprogress | 36,412,614.61 | 36,412,614.61 | |
| Productivebiologicalasset | |||
| Oilandgasasset | |||
| Right-of-useassets | 1,782,725,159.78 | 1,782,725,159.78 | |
| Intangibleassets | 319,207,126.15 | 318,693,082.72 | -514,043.43 |
| ExpenseonResearchandDevelopment | |||
| Goodwill | 833,547,800.60 | 833,547,800.60 | |
| Long-termprepaidexpenses | 311,328,706.46 | 311,328,706.46 | |
| Deferredtaxassets | 74,914,209.95 | 74,914,209.95 | |
| Othernon-currentasset | 72,365,863.71 | 58,168,919.11 | -14,196,944.60 |
| Totalnon-currentasset | 4,434,684,191.22 | 6,188,832,509.21 | 1,754,148,317.99 |
| Totalassets | 28,930,300,519.97 | 30,520,408,266.84 | 1,590,107,746.87 |
| Currentliabilities: | |||
| Short-termborrowings | 2,597,652,702.43 | 2,597,652,702.43 | |
| Loanfromcentralbank |
| Capitalborrowed | |||
| Transactionalfinancialliability | |||
| Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | |||
| Derivativefinancialliability | |||
| Notepayable | 3,416,755,681.80 | 3,416,755,681.80 | |
| Accountpayable | 6,468,535,961.17 | 6,468,535,961.17 | |
| Accountsreceivedinadvance | |||
| Contractualliability | 255,590,612.37 | 255,590,612.37 | |
| Sellingfinancialassetofrepurchase | |||
| Absorbingdepositandinterbankdeposit | |||
| Securitytradingofagency | |||
| Securitysalesofagency | |||
| Employeebenefitspayable | 231,866,407.40 | 231,866,407.40 | |
| Taxespayable | 241,980,412.72 | 241,980,412.72 | |
| Otheraccountpayable | 1,539,436,971.93 | 1,539,436,971.93 | |
| Incl:Interestpayable | 21,906,660.63 | 21,906,660.63 | |
| Dividendpayable | 6,389,320.96 | 6,389,320.96 | |
| Commissionchargeandcommissionpayable | |||
| Reinsurancepayable | |||
| Liabilityheldforsale | |||
| Non-currentliabilitiesduewithinoneyear | 5,861,324.37 | 495,132,751.96 | 489,271,427.59 |
| Othercurrentliabilities | 292,465.75 | 292,465.75 | |
| Totalcurrentliabilities | 14,757,972,539.94 | 15,247,243,967.53 | 489,271,427.59 |
| Non-currentliabilities: | |||
| Insurancecontractreserve |
| Long-termborrowings | 31,600,000.00 | 31,600,000.00 | |
| Bondspayable | |||
| Including:Preferredstock | |||
| Perpetualcapitalsecurities | |||
| Leaseliability | 1,104,600,297.80 | 1,104,600,297.80 | |
| Long-termpayable | 4,563,978.52 | 800,000.00 | -3,763,978.52 |
| Long-termemployeebenefitspayable | 2,050,000.00 | 2,050,000.00 | |
| Accrualliability | |||
| Deferredincome | 91,491,170.40 | 91,491,170.40 | |
| Deferredtaxliabilities | 67,605,161.88 | 67,605,161.88 | |
| Othernon-currentliabilities | 69,241,176.18 | 69,241,176.18 | |
| Totalnon-currentliabilities | 266,551,486.98 | 1,367,387,806.26 | 1,100,836,319.28 |
| Totalliabilities | 15,024,524,026.92 | 16,614,631,773.79 | 1,590,107,746.87 |
| Owner’sequity: | |||
| Sharecapital | 428,126,983.00 | 428,126,983.00 | |
| Otherequityinstrument | |||
| Including:Preferredstock | |||
| Perpetualcapitalsecurities | |||
| Capitalsurplus | 4,320,984,981.51 | 4,320,984,981.51 | |
| Less:Inventoryshares | |||
| Othercomprehensiveincome | |||
| Reasonablereserve | |||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 | |
| Provisionofgeneralrisk | |||
| Retainedearnings | 6,655,257,147.27 | 6,655,257,147.27 | |
| Shareholders’equityattributabletoshareholdersoftheparent | 11,618,432,603.28 | 11,618,432,603.28 | |
| Non-controlling | 2,287,343,889.77 | 2,287,343,889.77 |
| interests | |||
| Totalshareholders’equity | 13,905,776,493.05 | 13,905,776,493.05 | |
| Totalliabilitiesandshareholders’equity | 28,930,300,519.97 | 30,520,408,266.84 | 1,590,107,746.87 |
StatementofadjustmentBalanceSheetofParentCompany
InRMB
| Item | 2018-12-31 | 2019-01-01 | Adjustment |
| Currentassets: | |||
| Cashandbankbalances | 1,817,654,598.01 | 1,817,654,598.01 | |
| Tradablefinancialassets | |||
| Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses | |||
| Derivativefinancialassets | |||
| Notereceivable | 63,870,980.39 | 34,154,774.75 | -29,716,205.64 |
| Accountreceivable | 631,236,593.94 | 631,236,593.94 | |
| Receivablefinancing | 29,716,205.64 | 29,716,205.64 | |
| Advancestosuppliers | 4,760,182.00 | 4,757,318.66 | -2,863.34 |
| Otherreceivable | 1,541,980,883.50 | 1,541,980,883.50 | |
| Including:Interestreceivable | 7,550,877.07 | 7,550,877.07 | |
| Dividendreceivable | |||
| Inventories | 158,166,185.65 | 158,166,185.65 | |
| Contractualassets | |||
| Assetsheldforsale | |||
| Non-currentassetsmaturingwithinoneyear | |||
| Othercurrentassets | 39,482.38 | 39,482.38 | |
| Totalcurrentassets | 4,217,708,905.87 | 4,217,706,042.53 | -2,863.34 |
| Non-currentassets: | |||
| Debtinvestment | |||
| Available-for-salefinancialassets |
| Otherdebtinvestment | |||
| Held-to-maturityinvestments | |||
| Long-termreceivables | |||
| Long-termequityinvestments | 7,432,906,692.24 | 7,432,906,692.24 | |
| Investmentinotherequityinstrument | |||
| Othernon-currentfinancialassets | 140,000,000.00 | 140,000,000.00 | |
| Investmentproperties | 1,955,854.46 | 1,955,854.46 | |
| Fixedassets | 21,362,422.03 | 21,362,422.03 | |
| Constructioninprogress | |||
| Productivebiologicalassets | |||
| Oilandnaturalgasassets | |||
| Right-of-useassets | 6,827,171.38 | 6,827,171.38 | |
| Intangibleassets | 2,452,222.51 | 2,452,222.51 | |
| Researchanddevelopmentcosts | |||
| Goodwill | |||
| Long-termdeferredexpenses | 7,481,809.53 | 7,481,809.53 | |
| Deferredincometaxassets | |||
| Othernon-currentassets | 7,000,000.00 | 7,000,000.00 | |
| Totalnon-currentassets | 7,613,159,000.77 | 7,619,986,172.15 | 6,827,171.38 |
| Totalassets | 11,830,867,906.64 | 11,837,692,214.68 | 6,824,308.04 |
| Currentliabilities: | |||
| Short-termborrowings | 539,000,000.00 | 539,000,000.00 | |
| Transactionalfinancialliability | |||
| Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses |
| Derivativefinancialliability | |||
| Notespayable | 252,317,800.78 | 252,317,800.78 | |
| Accountpayable | 442,049,241.22 | 442,049,241.22 | |
| Accountsreceivedinadvance | |||
| Contractualliability | 4,182,083.40 | 4,182,083.40 | |
| Employeebenefitspayable | 36,233,563.12 | 36,233,563.12 | |
| Taxespayable | 13,426,601.90 | 13,426,601.90 | |
| Otherpayable | 1,481,817,856.56 | 1,481,817,856.56 | |
| Incl:Interestpayable | 1,354,592.35 | 1,354,592.35 | |
| Dividendspayable | |||
| Liabilityheldforsale | |||
| Non-currentliabilitiesduewithinoneyear | 786,068.44 | 786,068.44 | |
| Othercurrentliabilities | 226,427.99 | 226,427.99 | |
| Totalcurrentliabilities | 2,769,253,574.97 | 2,770,039,643.41 | 786,068.44 |
| Non-currentliabilities: | |||
| Long-termborrowings | 31,600,000.00 | 31,600,000.00 | |
| Bondspayable | |||
| Including:preferredstock | |||
| Perpetualcapitalsecurities | |||
| Leaseliabilities | 6,038,239.60 | 6,038,239.60 | |
| Long-termpayables | 800,000.00 | 800,000.00 | |
| Long-termemployeebenefitspayable | 118,000.00 | 118,000.00 | |
| Accruedliabilities | |||
| Deferredincome | 1,687,899.50 | 1,687,899.50 | |
| Deferredtaxliabilities | 2,298,426.39 | 2,298,426.39 | |
| Othernon-currentliabilities | |||
| Totalnon-currentliabilities | 36,504,325.89 | 42,542,565.49 | 6,038,239.60 |
| Totalliabilities | 2,805,757,900.86 | 2,812,582,208.90 | 6,824,308.04 |
| Owners’equity: | |||
| Sharecapital | 428,126,983.00 | 428,126,983.00 | |
| Otherequityinstrument | |||
| Including:preferredstock | |||
| Perpetualcapitalsecurities | |||
| Capitalsurplus | 4,426,362,777.26 | 4,426,362,777.26 | |
| Less:Inventoryshares | |||
| Othercomprehensiveincome | |||
| Specialreserve | |||
| Surplusreserve | 214,063,491.50 | 214,063,491.50 | |
| Retainedearnings | 3,956,556,754.02 | 3,956,556,754.02 | |
| Totalshareholders’equity | 9,025,110,005.78 | 9,025,110,005.78 | |
| Totalliabilitiesandshareholders’equity | 11,830,867,906.64 | 11,837,692,214.68 | 6,824,308.04 |
Statementofadjustment
2.Explanationoncomparativedataintheearlystageofretroactiveadjustmentwhileimplementedthenewfinancialinstrumentstandardsornewleasingstandardssince2019
□Applicable√Notapplicable
III.Auditreport
Whetherthe3
rdquarterlyreporthasbeenauditedornot
□Yes√NoThe3rdquarterlyreportoftheCompanyhasnotbeenaudited.
ChinaNationalAccordMedicinesCorporationLtd.
Legalrepresentative:LinZhaoxiong
24October2019